Half of patients hospitalized with severe COVID-19 across 302 UK hospitals developed one or more health complications within 28 days or discharge, according to a study yesterday in The Lancet.
A urine culture stewardship initiative at a teaching hospital in Michigan reduced overuse of urine cultures and was associated with a significant decline in catheter-associated urinary tract infections (CAUTIs), researchers reported today in Infection Control & Hospital Epidemiology.
The prevalence of the colistin-resistance gene MCR-1 in healthy residents of a Chinese city declined following China's ban on colistin as a growth promoter in livestock in 2017, researchers reported today in Clinical Microbiology and Infection. But seafood may be an emerging risk factor for MCR-1 colonization.
A modeling study yesterday suggests that the first human case of COVID-19 likely occurred in or around November 2019 in China, with the most likely date of origin being Nov 17. The study was published in PLOS Pathogens.
US intensive care unit (ICU) beds increased a net 10% amid the COVID-19 pandemic, from April to July 2020, over 2019 baselines, according to a study today in Infection Control & Hospital Epidemiology.
While one in four Washington, DC, child care facilities reported at least one COVID-19 case from July to December 2020, only 5.8% had COVID-19 facility-associated outbreaks, according to yesterday's Morbidity & Mortality Weekly Report. A facility-associated outbreak was defined as two or more lab-confirmed cases at a child care site within 14 days.
Antibiotic prescribing for young children in Israel sharply declined following implementation of pneumococcal conjugate vaccine (PCV), Israeli researchers reported today in Clinical Infectious Diseases.
An investigation into a Listeria moncytogenes outbreak linked to a New Jersey company's queso fresco cheese has ended, with 14 cases reported in four states, the US Centers for Disease Control and Prevention (CDC) said May 14 in a final update.
The researchers estimate a 40% increase in the annual incidence of resistant Salmonella.
The results of a phase 2b clinical trial indicate 77% efficacy over 12 months of follow-up for a vaccine that targets malaria caused by Plasmodium falciparum, according to a preprint study published this week in The Lancet.
